GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RespireRx Pharmaceuticals Inc (OTCPK:RSPI) » Definitions » Cyclically Adjusted Book per Share

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Cyclically Adjusted Book per Share : $-22.92 (As of Sep. 2023)


View and export this data going back to 2009. Start your Free Trial

What is RespireRx Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

RespireRx Pharmaceuticals's adjusted book value per share for the three months ended in Sep. 2023 was $-0.044. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-22.92 for the trailing ten years ended in Sep. 2023.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -44.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of RespireRx Pharmaceuticals was 1.70% per year. The lowest was -54.00% per year. And the median was -11.60% per year.

As of today (2024-05-22), RespireRx Pharmaceuticals's current stock price is $0.0008. RespireRx Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $-22.92. RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of RespireRx Pharmaceuticals was 0.40. The lowest was 0.01. And the median was 0.12.


RespireRx Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for RespireRx Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RespireRx Pharmaceuticals Cyclically Adjusted Book per Share Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.09 -10.12 -28.23 -31.88 -30.70

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.90 -30.70 -28.41 -25.75 -22.92

Competitive Comparison of RespireRx Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



RespireRx Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, RespireRx Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book= Book Value per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.044/129.8595*129.8595
=-0.044

Current CPI (Sep. 2023) = 129.8595.

RespireRx Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201312 -94.991 98.326 -125.455
201403 -52.231 99.695 -68.035
201406 -51.051 100.560 -65.926
201409 -47.969 100.428 -62.027
201412 -43.315 99.070 -56.777
201503 -45.209 99.621 -58.931
201506 -22.903 100.684 -29.540
201509 -16.201 100.392 -20.956
201512 -20.847 99.792 -27.128
201603 -26.494 100.470 -34.244
201606 -18.410 101.688 -23.510
201609 -24.113 101.861 -30.741
201612 -25.663 101.863 -32.716
201703 -25.920 102.862 -32.723
201706 -27.658 103.349 -34.753
201709 -26.241 104.136 -32.723
201712 -14.279 104.011 -17.828
201803 -16.006 105.290 -19.741
201806 -15.199 106.317 -18.565
201809 -14.996 106.507 -18.284
201812 -14.863 105.998 -18.209
201903 -16.141 107.251 -19.544
201906 -17.146 108.070 -20.603
201909 -18.200 108.329 -21.817
201912 -17.885 108.420 -21.422
202003 -2.218 108.902 -2.645
202006 -0.354 108.767 -0.423
202009 -0.127 109.815 -0.150
202012 -0.113 109.897 -0.134
202103 -0.095 111.754 -0.110
202106 -0.098 114.631 -0.111
202109 -0.105 115.734 -0.118
202112 -0.102 117.630 -0.113
202203 -0.111 121.301 -0.119
202206 -0.095 125.017 -0.099
202209 -0.097 125.227 -0.101
202212 -0.095 125.222 -0.099
202303 -0.085 127.348 -0.087
202306 -0.058 128.729 -0.059
202309 -0.044 129.860 -0.044

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


RespireRx Pharmaceuticals  (OTCPK:RSPI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of RespireRx Pharmaceuticals was 0.40. The lowest was 0.01. And the median was 0.12.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


RespireRx Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of RespireRx Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. The company also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.
Executives
David Dickason officer: SVP of Pre-Clinical Prod. Dev. 126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Timothy L. Jones director, officer: CEO and President 126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Manuso James S J director, officer: President & CEO 5130 ROUTE 212, WILLOW NY 12495
Katie Macfarlane director 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Purcell Richard David Jr. officer: SVP - Research & Deleopment 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Marc M Radin officer: Controller 33 FRANKLIN PLACE, GLEN ROCK NJ 07452
Robert N Weingarten director, officer: Vice President and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
Aurora Capital Llc other: Member of a 10% owner group 354 WIDOW GAVITS ROAD, PO BOX 1167, BRIDGEHAMPTON, NY 11932-1167
Aurora Capital Corp other: Member of 10% owner group
Jeff Eliot Margolis director, officer: Vice President, Sec. & Treas., other: Member of 10% owner group C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Steven Chizzik other: Member of 10% owner group C/O THE VERRAZANO GROUP, LLC, 2204 MORRIS AVENUE, SUITE 203A, UNION NJ 07083
Arnold Lippa director, officer: Chairman, CEO and President, other: Member of 10% owner group C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
T. Morgen Capital Llc other: Member of 10% owner group C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Kenneth M Cohen other: Member of 10% owner group 12750 HIGH BLUFF DRIVE, SUITE 310, SAN DIEGO CA 92130

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Headlines

From GuruFocus